Dr. Zang-Hee Cho received Ph.D. at Uppsala University (Sweden) in 1966 and has been faculty at the University of Stockholm and University of California-Los Angeles. In 1979, Dr. Cho moved to Columbia University as a Professor of Radiology (Physics) and served as a co-Director of Columbia University Imaging Center until 1984 before he joined University of California, Irvine (UCI). Since 1985, Dr. Cho was the Professor of Radiological Science at University of California at Irvine until 2006. From 2006 to 2014, Professor Cho, the University Professor at the Neuroscience Research Institute, Gachon University of Medicine & Science, Incheon, Korea. Dr. Cho moved to Advanced Institutes of Convergence Technology (AICT), Seoul National University, as a Distinguished Research Fellow, since 2015. Professor Cho has been a pioneer in Positron Emission Tomography (PET) and Magnetic Resonance Imaging since the inception of the computerized tomography (CT) in 1972. He was the first one who pioneered world’s first "Ring PET" in 1975 and its nuclear detector "Bismuth Germanate Oxide (BGO)" in 1976, both of which revolutionized modern brain-imaging. More recently, professor Cho pioneered the first PET-MRI (Proteomics 2008) demonstrating that in-vivo submillimeter high resolution molecular imaging is possible. This pioneering work now accepted as an important new approach to the molecular imaging in human brain imaging in-vivo. Among the numerous honors and awards, Professor Cho was elected as a member of the US National Academy of Sciences- Institute of Medicine in 1997.

Dr. George R. Lee received his medical degree from the Medical College of Georgia. He subsequently completed his internship in internal medicine at the University of Alabama, School of Medicine and his neurology residency at Vanderbilt University Medical Center. He continued his training at Vanderbilt University as a clinical neurophysiology fellow and served as the chief fellow. He currently holds an appointed position as Assistant Clinical Professor of Neurology with the Department of Neurology at Vanderbilt University Medical Center. He is the president and chairman of the board for Real Time Neuromonitoring Associates, PC and affiliated entities. He also serves as the medical director of the Vanderbilt Neurodiagnostic Technologist Training Program for which he helped found and obtain accreditation. His clinical focus is on providing intraoperative neuromonitoring and neurodiagnostic studies. Dr. Lee maintains licensure in Tennessee and 46 other states plus the District of Columbia. He has served on the Board of Directors of the American Society of Neurophysiological Monitoring (ASNM) and as its president and chairman of the board. He also has served on the board of the Tennessee Medical Association, board of Tennessee Medical Education Fund, Independent Medicine's Political Action Committee of Tennessee (IMPACT), the Tennessee Physician Leadership College Steering Committee, and the national Committee on Accreditation for Education in Neurodiagnostic Technology (CoA-NDT). He frequently presents at national and international conferences on the topics of intraoperative neuromonitoring practices, quality, evidence, medicolegal, and business. He has received leadership awards by the American Medical Association and the American Academy of Neurology and most recently received an outstanding entrepreneur award from Emory University.

Dr. Seabrook joined Janssen Pharmaceutical Companies of Johnson & Johnson in 2012 and is currently based at the J&J Innovation Center, South San Francisco, California. His role as the Global Lead for Neuroscience External Innovation is to create and implement the external innovation plan to deliver the Neuroscience Therapeutic Area R&D Strategy. He has 28 years of drug discovery experience that includes preclinical research on marketed products and candidates in clinical development. Previously, Guy was part of Eli Lilly’s Global External Research & Development organization where he led the GER&D team for the Lilly Bio-Medicines Business Unit. Formerly, at Merck & Co, he was the Head of the West Point Department of Alzheimer's disease Research. Guy graduated with a Ph.D. in Zoology from the University of Nottingham UK (1987) and completed his postdoctoral research at the University of Miami School of Medicine USA. He is a member of the British Pharmacological Society, The Physiological Society UK, and Biophysical Society, and has published over 90 peer reviewed papers and patent filings in the field.

Professor Rawlins is Watts Professor of Psychology, University of Oxford. His research is unusually wide ranging, extending from neuroanatomical and electrophysiological studies in rodents to cognitive psychology and fMRI paradigms in humans. His research has advanced our understanding of the neuropsychology, neurophysiology and neuroanatomy of memory, emotion, neurological diseases, and schizophrenia. His work on hippocampal function in rodents was important to define its connections in spatial working memory, object recognition and contextual learning. His hippocampal studies also yielded what became the standard tests for behavioural assessment of hippocampal damage. Recognising the opportunities arising from mouse genetics he characterised paradigms for use in murine studies. One important series of studies was his work demosntrating the early, pre-clinical effects of scrapie infection as this offered a method to test therapeutic intervention. His work has not been limited to rodents, He has pioneered novel uses of MRI to differentiate neural substrates undrelying the experience of pain and this has been used to investigate the overlapping and separate influences of pschological, phsyiological and pharmacological interventions. A key observation from his clinical studies was that studies on patients with schizophrenia need to be undertaken in drug naiive individuals if misleading results are to be avoided. In addition to his research achievements, he has played an important national role in neuroscience teaching and funding. In particular, he was a key figure, together with Professor David Attwell, in developing the four year taught PhD Programmes in Neuroscience at Oxford and UCL that attract excellent students and promise much for the future of UK neuroscience.

Jianguo Cheng, MD, PhD, is the President of American Academy of Pain Medicine (AAPM) and immediate past Chair of the US Section of World Institute of Pain. He has recently been appointed to the US Department of Health and Human Services (HHS) Pain Management Best Practices Inter-agency Task Force (PMTF) to propose updates to best practices and issue recommendations that address gaps or inconsistencies for managing chronic and acute pain. Dr. Cheng is also a member of the Centers for Medicare & Medicaid Services (CMS) Expert Work Group (EWG) to develop, specify, and maintain clinical quality measures.
As a physician investigator, Dr. Cheng has directed basic, translational, and clinical investigations of stem cells, opioid tolerance, and chronic pain. His research is supported by research grants from the National Institutes of Health (NIH), the Department of Defense, and other funding agencies.
Dr. Cheng has published more than 250 articles including investigations on opioid tolerance and neuropathic pain. As an educator, Dr. Cheng has published two textbooks (Springer-Nature) (Oxford University Press) and has given more than 150 lectures/presentations world-wide. He has trained more than 150 clinical pain fellows and postdoctoral research fellows. In addition, Dr. Cheng has played active leadership roles in the Association of University Anesthesiologists (AUA), American Board of Anesthesiology (ABA), American Society of Anesthesiologists (ASA), and American Academy of Regenerative Medicine. He has served as Senior Editor, Associate Editor, and Section Editor for the scientific journals of “Pain Medicine”, “Pain Practice”, and “Pain Physician”.
Dr. Cheng was trained in Pain Medicine at Harvard University (Fellowship at Massachusetts General Hospital), Surgery and Anesthesiology at University of Louisville (Residency), Neurology at the Qingdao University, and Neurosciences at the University of Guelph (PhD, Biophysics), University of Manitoba, and University of Alberta

After receiving his Medical Degree and Master of Science, Prof. Teng obtained his Ph.D. in Cell Biology/Neuroscience at Georgetown University, Washington DC, USA. For his postdoctoral training, he studied respiratory neurobiology, and stem cell biology and neurodegeneration at Georgetown University and Harvard Medical School, respectively. He is presently Director, Laboratory of Spinal Cord Injury (SCI) and Stem Cell Biology Research, Departments of Physical Medicine & Rehabilitation (PM&R) and Neurosurgery, Harvard Medical School/Spaulding Rehabilitation Hospital/Brigham & Women’s Hospital, and Director, Division of SCI Research, VA Boston Healthcare System (VABHS). He was elected President (2013-2014) of the American Society for Neural Therapy and Repair. Prof. Teng studies Functional Multipotency of Stem Cells and Recovery Neurobiology of Spinal Cord Injury via multimodal approaches that integrate stem cell biology, neurobiology, chemical engineering, neural oncology and molecular pharmacology. Work of his team has received the prestigious Apple Award of the American Spinal Injury Association (ASIA; 2011), the ERF New Investigator Award from the Foundation of Physical Medicine & Rehabilitation (2004), the Annual Research Award from the Congress of Neurological Surgeons (CNS; 2001), and the Mayfield Award (2012) and Larson Award (2015, 2016) from the American Association of Neurological surgeons/Congress of Neurological Surgeons (AANS/CNS) Joint Section on Disorders of the Spine and Peripheral Nerves.